antihemophilic factor (coagulation factor VIII, AHF-M, Hemofil, Humate-P, Monoclate-P)
Jump to navigation
Jump to search
Introduction
Tradenames: AHF-M, Hemofil, Humate-P, Monoclate-P, Advate*
Indications
- management of hemophilia A
Contraindications
- hypersensitivity to mouse proteins (preparation contains trace amounts of mouse protein*
Dosage
- individualize dose based upon coagulation studies
- one unit will increase circulating AHF by 2%
- hospitalized patients:
- 20-50 units/kg/dose
- may be given every 12-24 hours & more frequently in special circumstances
AHF units = body weight (kg) x desired AHF increase (%) x 0.5
* Advate (Baxter) is free of plasma & albumin[5]
Pharmacokinetics
Adverse effects
- uncommon (< 1%)
- flushing, tachycardia, headache, nausea/vomiting, paresthesia, allergic vasomotor reactions, tightness in neck or chest
More general terms
More specific terms
Additional terms
- coagulation cascade
- coagulation factor VIII autoantibody (acquired hemophilia)
- coagulation factor VIIIa
- von Willebrand factor; vWF; ristocetin cofactor; factor VIII related antigen; contains: von Willebrand antigen 2 (VWF, F8VWF)
References
- ↑ Walker FJ, Fay PJ. Regulation of blood coagulation by the protein C system. FASEB J. 1992 May;6(8):2561-7. Review. PMID: https://www.ncbi.nlm.nih.gov/pubmed/1317308
- ↑ Andrews BS. Is the WKS motif the tissue-factor binding site for coagulation factor VII? Trends Biochem Sci. 1991 Jan;16(1):31-6. Review. PMID: https://www.ncbi.nlm.nih.gov/pubmed/2053135
- ↑ Kaiser Permanente Northern California Regional Drug Formulary, 1998
- ↑ Medical Knowledge Self Assessment Program (MKSAP) 11, 18. American College of Physicians, Philadelphia 1998, 2018,
- ↑ 5.0 5.1 Prescriber's Letter 11(2):suppl 2004
- ↑ Department of Veterans Affairs, VA National Formulary